Galderma stock: Citi sets CHF 185.00 target for Galderma stock

Published on 10/20/2026 at 17:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached CHF 3.07 billion in the second quarter, up from CHF 2.64 billion. Galderma stock costs EUR 188.50 on October 20, 2026 at Lang & Schwarz.

Analyst target and reporting date

Citi set a CHF 185.00 target for Galderma on October 16, 2026.
Second-quarter revenue reached CHF 3.07 billion versus CHF 2.64 billion a year earlier.
Galderma stock costs EUR 188.50 at Lang & Schwarz on October 20, 2026 at 5:05 p.m. CEST.
Galderma is scheduled to release third-quarter sales and revenue on October 21, 2026.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma stock (ISIN CH1335392721) was trading at EUR 188.50 at Lang & Schwarz on October 20, 2026 at 5:05 p.m. CEST. On October 16, 2026, Citi analyst Cedric Besnard initiated coverage with a Buy rating and a CHF 185.00 price target, according to Markets Insider. The target is 5.47 percent above the SIX price of CHF 175.40 at 4:54 p.m. CEST.

Revenue growth supports the case

Galderma reported CHF 3.07 billion in quarterly revenue for the period ending June 30, 2026, compared with CHF 2.64 billion a year earlier. That represents growth of 16.29 percent. The figures were carried by Markets Insider in its report on the Citi initiation.

Stock sits near its yearly high

Galderma traded between CHF 96.50 and CHF 188.25 over the 52 weeks through October 20, 2026. Its SIX market capitalization was CHF 40.9 billion, with a price-to-earnings ratio of 58.41. The CHF 175.40 share price stood 6.83 percent below the 52-week high, leaving the valuation sensitive to the company meeting its growth plans.

Next report arrives October 21

Galderma is scheduled to release third-quarter sales and revenue on October 21, 2026, according to MarketScreener. The date gives investors the next test for revenue momentum and margin delivery. Galderma also remains a member of the Swiss Market Index, as Galderma reported on September 21, 2026.

Comparison with peers

Galderma: 0.98 percent higher on SIX, P/E 58.41, market capitalization CHF 40.9 billion.

Novartis: 1.61 percent higher on SIX, P/E 23.32, market capitalization CHF 239.9 billion.

AbbVie: 2.02 percent higher on NYSE, P/E 81.34, market capitalization USD 509.6 billion.

Target and price in view

Citi's CHF 185.00 target is 5.47 percent above the SIX price of CHF 175.40, while the Lang & Schwarz euro quote provides the German trading perspective for the stock. The next scheduled report is the immediate event date for assessing whether revenue growth remains consistent with the analyst case. Galderma was trading at EUR 188.50 at Lang & Schwarz on October 20, 2026 at 5:05 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.